Novo Nordisk A/S vs Warner Music Group Corp — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Warner Music Group Corp trades at $28.72 (market cap $15.12B). The key difference: Novo Nordisk A/S is far larger — about 10.9× Warner Music Group Corp's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Warner Music Group Corp for 96 Days on average.
| NVO | WMG | |
|---|---|---|
Market Cap | $165.31B | $15.12B |
Volume | 11,432,838 | 2,966,414 |
Sector | Health | Media |
52-Week High | $63.98 | $34.72 |
52-Week Low | $35.29 | $23.65 |
Typical Hold Time | 116 Days | 96 Days |
Enterprise Value | $179.56B | $19.42B |
Dividend Yield | 4.71% | 2.77% |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Warner Music Group (WMG) trades at $28.91, up 2.66% on the day, with a bullish technical outlook and strong analyst support. Recent earnings have beaten expectations, with Q2 2026 EPS of $0.38 exceeding the $0.3435 forecast. The company's revenue growth is solid, projected to reach $7.3B in 2026, and it maintains a high return on equity of 92.72%. Positive news includes strategic AI partnerships and a renewed licensing deal with NetEase Cloud Music.
The stock presents a compelling opportunity with a consensus price target of $39.50, implying significant upside. However, risks include recent net cash outflows, a high P/E ratio of 23.12, and competitive pressures in the evolving music industry. Investor sentiment is buoyed by institutional buying and AI-driven growth prospects, but execution on cost management and streaming market share remains critical.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →